BioXcel Therapeutics (BTAI) Other financing activities (2019 - 2026)

BioXcel Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 166.49% increase from a year earlier, with the FY2024 full-year figure at $2.5 million, up 400.0% from the prior year.
• Other financing activities climbed to $6.2 million in Q1 2026 per BTAI's latest filing, from $2.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $6.2 million in Q1 2026 and bottomed at $48000.0 in Q3 2022.
• The 4-year median for Other financing activities is $1.3 million (2023), against an average of $1.9 million.
• Across the five-year window, Other financing activities soared 552.92% in 2022 and plunged 92.3% in 2023, its largest moves.
• Year by year, Other financing activities stood at $3.0 million in 2022, then tumbled by 91.7% to $250000.0 in 2023, then surged by 826.4% to $2.3 million in 2024, then jumped by 166.49% to $6.2 million in 2026.
• Per Business Quant, the three latest BTAI Other financing activities figures stand at $6.2 million (Q1 2026), $2.3 million (Q4 2024), and $224000.0 (Q1 2024).